Do Analysts Expect Recursion Pharmaceuticals Inc (RXRX) Stock to Rise After It Is Lower By -9.12% in a Month?

InvestorsObserver is giving Recursion Pharmaceuticals Inc (RXRX) an Analyst Rating Rank of 18, meaning RXRX is ranked higher by analysts than 18% of stocks. The average price target for RXRX is $13.6 and analyst’s rate the stock as a Buy.

Wall Street analysts are rating RXRX a Buy today. Find out what this means to you and get the rest of the rankings on RXRX!

See Full RXRX Report

Why are Analyst Ratings Important?

You can learn a lot about a company from looking at it’s financial statements and comparing them to other companies. Analysts who cover an industry in depth can add even more to your research though. They typically follow a particular sector or industry very closely. They also pay attention to and ask questions on earnings conference calls and other events where they might learn information that does show up in the numbers. InvestorsObserver takes the average rating from these analysts, and then percentile ranks those averages. This lets you compare stocks in a much more granular way than just seeing the typical five-tiered rating system used on most of Wall Street.

What's Happening With Recursion Pharmaceuticals Inc Stock Today?

Recursion Pharmaceuticals Inc (RXRX) stock is trading at $7.57 as of 12:10 PM on Thursday, Mar 16, a gain of $0.09, or 1.2% from the previous closing price of $7.48. The stock has traded between $7.33 and $7.71 so far today. Volume today is light. So far 241,757 shares have traded compared to average volume of 954,909 shares. Click Here to get the full Stock Report for Recursion Pharmaceuticals Inc stock.